laboratory mice without an active FMR1 gene, like in Fragile X syndrome, but with a reduced amount of mGluR5 protein. The mice showed an improvement in their brain structure and function, in their brains' ability to make key proteins, and in memory and body growth. This shows that the over-activation of mGluR5 is very important in Fragile X syndrome, and suggests a path for drug development to treat the syndrome.
In the current study, twelve participants recruited by Rush and the University of California, Davis received a single oral dose of 50-to-150 mg of fenobam. Prepulse inhibition (PPI) and continuous performance test (CPT) were obtained before and after dosing to explore the effects of fenobam on measures of sensory gating, attention and inhibition. In six of the 12 individuals there was a 20 percent improvement.
"Currently, there are no therapies on the market to treat cognitive deficits associated with Fragile X syndrome," said Berry-Kravis. "This pilot study has identified the potential beneficial clinical effects of fenobam, but further research is needed."
'/>"/>
Page: 1 2 Related biology news :1.
UIC researchers find promising new targets for antibiotics2.
New book defines promising young field of adult neurogenesis3.
Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging4.
Cancer and arthritis therapy may be promising treatment for diabetes5.
Unique whey protein is promising supplement for strict PKU diet6.
Promising new drug targets identified for Huntingtons disease7.
Promising new nanotechnology for spinal cord injury8.
Biodesigns Rittmann offers promising perspectives on societys energy challenge9.
UIC researchers make promising finding in severe lung disease10.
New treatment approach promising for lymphoma patients in the developing world11.
Immunotherapy in high-risk pediatric sarcomas shows promising response